The stress response as a target for treatment of central serous chorioretinopathy

References

• Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans. Am. Ophthalmol. Soc. 84, 799–845 (1986).
   PubMedGoogle Scholar
• Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115(1), 169–173 (2008).
   PubMed Web of Science ®Google Scholar
• Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am. J. Psychiatry 144(1), 46–50 (1987).
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 24(12), 1743–1756 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv. Ophthalmol. 58(2), 103–126 (2013).
   PubMed Web of Science ®Google Scholar
• Bujarborua D, Borooah S, Dhillon B. Getting serious with retinopathy: Approaching an integrated hypothesis for central serous chorioretinopathy. Med. Hypotheses 81(2), 268–273 (2013).
   PubMed Web of Science ®Google Scholar
• Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Central serous chorioretinopathy: a pathogenetic model. Clin. Ophthalmol. 5, 239–243 (2011).
   PubMedGoogle Scholar
• Wang M, Munch Ic, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 86(2), 126–145 (2008).
   PubMed Web of Science ®Google Scholar
• Todd KC, Hainsworth DP, Lee LR, Madsen RW. Longitudinal analysis of central serous chorioretinopathy and sex. Can. J. Ophthalmol. 37(7), 405–408 (2002).
   PubMed Web of Science ®Google Scholar
• Wynn Pa. Idiopathic central serous chorioretinopathy – a physical complication of stress? Occup. Med. (Lond) 51(2), 139–140 (2001).
   PubMed Web of Science ®Google Scholar
• Marmor MF. New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefes Arch. Clin. Exp. Ophthalmol. 226(6), 548–552 (1988).
   PubMed Web of Science ®Google Scholar
• Burchfield SR. The stress response: a new perspective. Psychosom. Med. 41(8), 661–672 (1979).
   PubMed Web of Science ®Google Scholar
• Ventura LM. Psychoneuroimmunology: application to ocular diseases. J. Ocul. Biol. Dis. Inform. 2, 109–118 (2009).
   Google Scholar
• Watson CS, Gametchu B. Proteins of multiple classes may participate in nongenomic steroid actions. Exp. Biol. Med. (Maywood) 228(11), 1272–1281 (2003).
   PubMed Web of Science ®Google Scholar
• Lipowski ZJ, Kiriakos Rz. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12(6), 398–401 (1971).
   PubMed Web of Science ®Google Scholar
• Horniker E. Su di una forma retinite centrale di origine vasoneurotica (retinite central capillaro spastica). Ann. Otol. Rhinol. Laryngol. 55 578–600 (1927).
   Google Scholar
• Cordes F. A type of foveo-macular retinitis observed in the US Navy. American Journal of Ophthalmology (27), 803–816 (1944).
   Google Scholar
• Harrington DO. Psychosomatic inter-relationships in ophthalmology. Am. J. Ophthal. 31, 1241–1251 (1948).
   PubMedGoogle Scholar
• Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom. Med. 9(2), 110–117 (1947).
   PubMed Web of Science ®Google Scholar
• Hartmann E. [Central angiospastic retinopathy]. Bull. Soc. Ophtalmol. Fr. 2, 110–120 (1953).
   PubMedGoogle Scholar
• Tittl MK, Spaide RF, Wong D et al. Systemic findings associated with central serous chorioretinopathy. Am. J. Ophthalmol. 128(1), 63–68 (1999).
   PubMed Web of Science ®Google Scholar
• Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(3 Suppl.), 1–139 (1967).
   Google Scholar
• Conrad R, Bodeewes I, Schilling G, Geiser F, Imbierowicz K, Liedtke R. [Central serous chorioretinopathy and psychological stress]. Ophthalmologe 97(8), 527–531 (2000).
   PubMed Web of Science ®Google Scholar
• Bennett G. Central serous retinopathy. Br. J. Ophthalmol. 39(10), 605–618 (1955).
   PubMedGoogle Scholar
• Bujarborua D, Choudhury A. Diffuse retinal pigment epitheliopathy among the inhabitants of Brahmaputra Valley of India. Eur. J. Ophthalmol. 18(4), 578–586 (2008).
   PubMed Web of Science ®Google Scholar
• Bujarborua D, Nagpal Pn, Deka M. Smokestack leak in central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 248(3), 339–351 (2010).
   PubMed Web of Science ®Google Scholar
• Gass Jd, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102(5), 737–747 (1995).
   PubMed Web of Science ®Google Scholar
• Makara GB. Mechanisms by which stressful stimuli activate the pituitary-adrenal system. Fed. Proc. 44(1 Pt 2), 149–153 (1985).
   PubMedGoogle Scholar
• Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br. J. Ophthalmol. 87(6), 704–708 (2003).
   PubMed Web of Science ®Google Scholar
• Conrad R, Weber NF, Lehnert M, Holz FG, Liedtke R, Eter N. Alexithymia and emotional distress in patients with central serous chorioretinopathy. Psychosomatics 48(6), 489–495 (2007).
   PubMed Web of Science ®Google Scholar
• Pomerleau OF, Pomerleau CS. Behavioural studies in humans: anxiety, stress and smoking. Ciba Found. Symp. 152, 225–235; discussion 235–229 (1990).
   PubMedGoogle Scholar
• Friedman M, Byers SO, Diamant J, Rosenman RH. Plasma catecholamine response of coronary-prone subjects (type A) to a specific challenge. Metabolism 24(2), 205–210 (1975).
   PubMed Web of Science ®Google Scholar
• Friedman M, St George S, Byers SO, Rosenman RH. Excretion of catecholamines, 17-ketosteroids, 17-hydroxycorticoids and 5-hydroxyindole in men exhibiting a particular behavior pattern (A) associated with high incidence of clinical coronary artery disease. J. Clin. Invest. 39, 758–764 (1960).
   PubMed Web of Science ®Google Scholar
• Friedlander L, Lumley MA, Farchione T, Doyal G. Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. J. Nerv. Ment. Dis. 185(4), 233–239 (1997).
   PubMed Web of Science ®Google Scholar
• Jula A, Salminen JK, Saarijarvi S. Alexithymia: a facet of essential hypertension. Hypertension 33(4), 1057–1061 (1999).
   PubMed Web of Science ®Google Scholar
• Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111(2), 244–249 (2004).
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch. Clin. Exp. Ophthalmol. 236(8), 571–576 (1998).
   PubMed Web of Science ®Google Scholar
• Tewari Hk, Gadia R, Kumar D, Venkatesh P, Garg Sp. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest. Ophthalmol. Vis. Sci. 47(8), 3474–3478 (2006).
   PubMed Web of Science ®Google Scholar
• Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br. J. Ophthalmol. 81(11), 962–964 (1997).
   PubMed Web of Science ®Google Scholar
• Mayo GL, Tolentino Mj. Images in clinical medicine. Central serous chorioretinopathy in pregnancy. N. Engl J. Med. 353(7), e6 (2005).
   PubMed Web of Science ®Google Scholar
• Michael JC, Pak J, Pulido J, De Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am. J. Ophthalmol. 136(1), 182–185 (2003).
   PubMed Web of Science ®Google Scholar
• Leveque TK, Yu L, Musch DC, Chervin RD, Zacks DN. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath 11(4), 253–257 (2007).
   PubMed Web of Science ®Google Scholar
• Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 246(9), 1225–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Grover DP. Obstructive sleep apnea and ocular disorders. Curr. Opin. Ophthalmol. 21(6), 454–458 (2010).
   PubMed Web of Science ®Google Scholar
• Grunstein RR. Metabolic aspects of sleep apnea. Sleep 19(10 Suppl.), S218–S220 (1996).
   Web of Science ®Google Scholar
• Fletcher EC, Miller J, Schaaf JW, Fletcher JG. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep 10(1), 35–44 (1987).
   PubMed Web of Science ®Google Scholar
• Fletcher EC. Sympathetic activity and blood pressure in the sleep apnea syndrome. Respiration 64( Suppl. 1), 22–28 (1997).
   PubMed Web of Science ®Google Scholar
• Dimsdale JE, Coy T, Ancoli-Israel S, Mills P, Clausen J, Ziegler MG. Sympathetic nervous system alterations in sleep apnea. The relative importance of respiratory disturbance, hypoxia, and sleep quality. Chest 111(3), 639–642 (1997).
   PubMed Web of Science ®Google Scholar
• Spath-Schwalbe E, Gofferje M, Kern W, Born J, Fehm Hl. Sleep disruption alters nocturnal ACTH and cortisol secretory patterns. Biol. Psychiatry 29(6), 575–584 (1991).
   PubMed Web of Science ®Google Scholar
• Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 354(9188), 1435–1439 (1999).
   PubMed Web of Science ®Google Scholar
• Jain Ak, Kaines A, Schwartz S. Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch. Clin. Exp. Ophthalmol. 248(7), 1037–1039 (2010).
   PubMed Web of Science ®Google Scholar
• Mansuetta CC, Mason JO3rd, Swanner J et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol 137(6), 1096–1100 (2004).
   PubMed Web of Science ®Google Scholar
• Mann RM, Riva CE, Stone RA, Barnes GE, Cranstoun SD. Nitric oxide and choroidal blood flow regulation. Invest. Ophthalmol. Vis. Sci. 36(5), 925–930 (1995).
   PubMed Web of Science ®Google Scholar
• Hardy P, Lamireau D, Hou X et al. Major role for neuronal NO synthase in curtailing choroidal blood flow autoregulation in newborn pig. J. Appl. Physiol. 91(4), 1655–1662 (2001).
   PubMed Web of Science ®Google Scholar
• Arndt C, Sari A, Ferre M et al. Electrophysiological effects of corticosteroids on the retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 42(2), 472–475 (2001).
   PubMed Web of Science ®Google Scholar
• Sibayan Sa, Kobuch K, Spiegel D et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 238(6), 515–519 (2000).
   PubMed Web of Science ®Google Scholar
• Cotticelli L, Borrelli M, D'alessio AC et al. Central serous chorioretinopathy and Helicobacter pylori. Eur. J. Ophthalmol. 16(2), 274–278 (2006).
   PubMed Web of Science ®Google Scholar
• Giusti C, Mauget-Faysse M. Helicobacter pylori and idiopathic central serous chorioretinopathy. Swiss. Med. Wkly. 134(27–28), 395–398 (2004).
   PubMed Web of Science ®Google Scholar
• Keates S, Sougioultzis S, Keates Ac et al. cag+ Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J. Biol. Chem. 276(51), 48127–48134 (2001).
   PubMed Web of Science ®Google Scholar
• Misiuk-Hojlo M, Michalowska M, Turno-Krecicka A. Helicobacter pylori – a risk factor for the developement of the central serous chorioretinopathy. Klin. Oczna. 111(1–3), 30–32 (2009).
   PubMedGoogle Scholar
• Wassermann Ge, Olivera-Severo D, Uberti Af, Carlini Cr. Helicobacter pylori urease activates blood platelets through a lipoxygenase-mediated pathway. J. Cell. Mol. Med. 14(7), 2025–2034 (2010).
   PubMed Web of Science ®Google Scholar
• Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol. Vis. 17, 99–103 (2011).
   PubMed Web of Science ®Google Scholar
• Costen Mt, Olson Ja. Central serous chorioretinopathy may be a manifestation of the primary antiphospholipid syndrome. Br. J. Ophthalmol. 84(6), 667 (2000).
   PubMed Web of Science ®Google Scholar
• Nucci C, Corsi A, Mancino R, Macri G. Central serous chorioretinopathy in patients with psoriasis. Acta. Ophthalmol. Scand. 82(1), 105–107 (2004).
   PubMedGoogle Scholar
• Bouzas EA, Scott MH, Mastorakos G, Chrousos Gp, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch. Ophthalmol. 111(9), 1229–1233 (1993).
   PubMedGoogle Scholar
• Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br. J. Ophthalmol. 68(5), 329–331 (1984).
   PubMed Web of Science ®Google Scholar
• Carvalho-Recchia Ca, Yannuzzi La, Negrao S et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 109(10), 1834–1837 (2002).
   PubMed Web of Science ®Google Scholar
• Koyama M, Mizota A, Igarashi Y, Adachi-Usami E. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Ophthalmologica 218(2), 107–110 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Katsume Y, Akune H. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. Ophthalmologica 185(3), 168–178 (1982).
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Katsume Y. Experimental central serous chorioretinopathy: III. Ultrastructural findings. Jpn. J. Ophthalmol. 26, 397–409 (1982).
   PubMed Web of Science ®Google Scholar
• Beato M, Arnemann J, Chalepakis G, Slater E, Willmann T. Gene regulation by steroid hormones. J. Steroid Biochem. 27(1–3), 9–14 (1987).
   PubMedGoogle Scholar
• Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101(1), 227–232 (2004).
   PubMed Web of Science ®Google Scholar
• Verma L, Purohit A, Tewari Hk et al. A study of endogenous cortislo profile in patients with central serous retinopathy with single and multiple leaks. Indian J. Pharmacol. 33, 96–99 (2001).
   Google Scholar
• Zakir SM, Shukla M, Simi ZU, Ahmad J, Sajid M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J. Ophthalmol. 57(6), 419–422 (2009).
   PubMed Web of Science ®Google Scholar
• Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110(4), 698–703 (2003).
   PubMed Web of Science ®Google Scholar
• Sun J, Tan J, Wang Z, Yang H, Zhu X, Li L. Effect of catecholamine on central serous chorioretinopathy. J. Huazhong Univ. Sci. Technolog. Med. Sci. 23(3), 313–316 (2003).
   PubMedGoogle Scholar
• Rocha EM, Wickham LA, Da Silveira LA et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br. J. Ophthalmol. 84(1), 76–84 (2000).
   PubMed Web of Science ®Google Scholar
• Ahad MA, Chua CN, Evans NM. Central serous chorioretinopathy associated with testosterone therapy. Eye (Lond). 20(4), 503–505 (2006).
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in central serous chorioretinopathy. Br. J. Ophthalmol. 91(1), 118–119 (2007).
   PubMed Web of Science ®Google Scholar
• Forooghian F, Meleth Ad, Cukras C, Chew Ey, Wong Wt, Meyerle Cb. Finasteride for chronic central serous chorioretinopathy. Retina 31(4), 766–771 (2011).
   PubMed Web of Science ®Google Scholar
• Bill A, Sperber Go. Control of retinal and choroidal blood flow. Eye (Lond). 4 ( Pt 2), 319–325 (1990).
   PubMed Web of Science ®Google Scholar
• Matsuura M, Ando F. [Stellate ganglion block therapy in central serous chorioretinopathy (author's transl)]. Nihon Ganka Gakkai Zasshi 85(9), 1485–1491 (1981).
   PubMedGoogle Scholar
• Kim CS, Park CM, Suh JH, Kim SN. Stellate ganglion block for treatment of central serous chorioretinopathy. J. Korean Pain. Soc. 8(2), 324–327 (1995).
   Google Scholar
• Ghiadoni L, Donald Ae, Cropley M et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 102(20), 2473–2478 (2000).
   PubMed Web of Science ®Google Scholar
• Spieker LE, Hurlimann D, Ruschitzka F et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 105(24), 2817–2820 (2002).
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Kop WJ, Hausner E, Mcceney MK, Herrington D, Krantz DS. Effects of mental stress on flow-mediated brachial arterial dilation and influence of behavioral factors and hypercholesterolemia in subjects without cardiovascular disease. Am. J. Cardiol. 92(6), 687–691 (2003).
   PubMed Web of Science ®Google Scholar
• De Hoz Montañana R, Ramírez Sebastián AI. Implications of nerve control of choroidal blood flow in ocular diseases. Archivos de la Sociedad Española de Oftalmología 81, 241–242 (2006).
   PubMedGoogle Scholar
• Hayashi K Hy, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int. Ophthalmol. 9, 37–41 (1986).
   PubMed Web of Science ®Google Scholar
• Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am. J. Ophthalmol. 121(1), 26–34 (1996).
   PubMed Web of Science ®Google Scholar
• Spaide Rf, Hall L, Haas A et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16(3), 203–213 (1996).
   PubMed Web of Science ®Google Scholar
• Piccolino Fc, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye (Lond). 9 ( Pt 3), 324–332 (1995).
   PubMed Web of Science ®Google Scholar
• Yamada R, Yamada S, Ishii A, Tane S. [Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy]. Nihon Ganka Gakkai Zasshi 97(8), 955–960 (1993).
   PubMedGoogle Scholar
• Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am. J. Ophthalmol. 127(4), 477–478 (1999).
   PubMed Web of Science ®Google Scholar
• Raikkonen K, Lassila R, Keltikangas-Jarvinen L, Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler. Thromb. Vasc. Biol. 16(3), 363–367 (1996).
   PubMed Web of Science ®Google Scholar
• Tsai Sj, Hong Cj, Liou Yj, Yu Yw, Chen Tj. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet. Genomics 18(10), 869–875 (2008).
   PubMed Web of Science ®Google Scholar
• Casonato A, Pontara E, Bertomoro A, Sartorello F, Girolami A. Which assay is the most suitable to investigate von Willebrand factor activity? Thromb. Haemost. 81, 994–995 (1999).
   PubMed Web of Science ®Google Scholar
• Gopal S, Garibaldi S, Goglia L et al. Estrogen regulates endothelial migration via plasminogen activator inhibitor (PAI-1). Mol. Hum. Reprod. 18(8), 410–416 (2012).
   PubMed Web of Science ®Google Scholar
• Guyer Dr, Yannuzzi La, Slakter Js, Sorenson Ja, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch. Ophthalmol. 112(8), 1057–1062 (1994).
   PubMedGoogle Scholar
• Klein B. Macular and extramacular serous chorioretinopathy. Am. J. Ophthalmol. 51, 231–242 (1961).
   PubMed Web of Science ®Google Scholar
• Stern Wh, Ernest Jt. Microsphere occlusion of the choriocapillaris in rhesus monkeys. Am J. Ophthalmol. 78(3), 438–448 (1974).
   PubMed Web of Science ®Google Scholar
• Friedman M, Rosenman Rh, Byers S. Serum lipids and conjunctival circulation after fat ingestion in men exhibiting type-a behavior pattern. Circulation 29, 874–886 (1964).
   PubMed Web of Science ®Google Scholar
• Dvorak Hf, Nagy Ja, Feng D, Brown Lf, Dvorak Am. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97–132 (1999).
   PubMed Web of Science ®Google Scholar
• Dvorak Am, Kohn S, Morgan Es, Fox P, Nagy Ja, Dvorak Hf. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 59(1), 100–115 (1996).
   PubMed Web of Science ®Google Scholar
• Alomran Ms. Intravitreal Bevacizumab for the treatment of central serous chorioretinopathy. Ophthalmic. Surg. Lasers Imaging 1–3 (2010).
   PubMedGoogle Scholar
• Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr. Eye Res. 35(2), 91–98 (2010).
   PubMed Web of Science ®Google Scholar
• Torres-Soriano Me, Garcia-Aguirre G, Kon-Jara V et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch. Clin. Exp. Ophthalmol. 246(9), 1235–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Lim Sj, Roh Mi, Kwon Ow. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 30(1), 100–106 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Zy, Shen Lj, Tu L et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic. Biol. Med. 46(8), 1032–1041 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Ramirez M, Hernandez C, Simo R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 31(6), 1189–1194 (2008).
   PubMed Web of Science ®Google Scholar
• Ksiazek A, Zaluska Wt, Ksiazek P. Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin. Nephrol. 56(2), 104–110 (2001).
   PubMed Web of Science ®Google Scholar
• Garcia-Ramirez M, Hernandez C, Ruiz-Meana M et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/ PI3K signaling. Cell. Signal 23(10), 1596–1602 (2011).
   PubMed Web of Science ®Google Scholar
• Ray Pd, Huang Bw, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal 24(5), 981–990 (2012).
   PubMed Web of Science ®Google Scholar
• Nwose Eu, Ewing Gw. Computer diagnosis in cardiology: oxidative stress hypothesis. N. Am. J. Med. Sci. 1(5), 220–225 (2009).
   PubMedGoogle Scholar
• Strauss O. The retinal pigment epithelium in visual function. Physiol. Rev. 85(3), 845–881 (2005).
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen D, Wang Vm et al. Enhanced apoptosis in retinal pigment epithelium under inflammatory stimuli and oxidative stress. Apoptosis 17(11), 1144–1155 (2012).
   PubMed Web of Science ®Google Scholar
• Chen M, Forrester Jv, Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp. Eye Res. 84(4), 635–645 (2007).
   PubMed Web of Science ®Google Scholar
• Krohne Tu, Stratmann Nk, Kopitz J, Holz Fg. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp. Eye Res. 90(3), 465–471 (2010).
   PubMed Web of Science ®Google Scholar
• Yang D, Elner Sg, Chen X, Field Mg, Petty Hr, Elner Vm. MCP-1-activated monocytes induce apoptosis in human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 52(8), 6026–6034 (2011).
   PubMed Web of Science ®Google Scholar
• Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am. J. Ophthalmol. 149(3), e441–e442 (2010).
   PubMed Web of Science ®Google Scholar
• Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch. Clin. Exp. Ophthalmol. 224(4), 321–324 (1986).
   PubMed Web of Science ®Google Scholar
• Ahlers C, Geitzenauer W, Stock G, Golbaz I, Schmidt-Erfurth U, Prunte C. Alterations of intraretinal layers in acute central serous chorioretinopathy. Acta. Ophthalmol. 87(5), 511–516 (2009).
   PubMed Web of Science ®Google Scholar
• Frambach Da, Fain Gl, Farber Db, Bok D. Beta adrenergic receptors on cultured human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 31(9), 1767–1772 (1990).
   PubMed Web of Science ®Google Scholar
• Friedman Z, Hackett Sf, Campochiaro Pa. Characterization of adenylate cyclase in human retinal pigment epithelial cells in vitro. Exp. Eye Res. 44(4), 471–479 (1987).
   PubMed Web of Science ®Google Scholar
• Marmor Mf, Yao Xy. The metabolic dependency of retinal adhesion in rabbit and primate. Arch. Ophthalmol. 113(2), 232–238 (1995).
   PubMedGoogle Scholar
• Sharma T, Shah N, Rao M et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111(9), 1708–1714 (2004).
   PubMed Web of Science ®Google Scholar
• Meyerle Cb, Freund Kb, Bhatnagar P, Shah V, Yannuzzi La. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27(7), 943–946 (2007).
   PubMed Web of Science ®Google Scholar
• Nielsen Js, Jampol Lm. Oral mifepristone for chronic central serous chorioretinopathy. Retina 31(9), 1928–1936 (2011).
   PubMed Web of Science ®Google Scholar
• Zhao M, Celerier I, Bousquet E et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 122(7), 2672–2679 (2012).
   PubMed Web of Science ®Google Scholar
• Steinle Nc, Gupta N, Yuan A, Singh Rp. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br. J. Ophthalmol. 96(1), 10–13 (2012).
   PubMed Web of Science ®Google Scholar
• Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med. Hypotheses 73(3), 435–437 (2009).
   PubMed Web of Science ®Google Scholar
• Seong Hk, Bae Jh, Kim Es, Han Jr, Nam Wh, Kim Hk. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 223(5), 343–347 (2009).
   PubMed Web of Science ®Google Scholar
• Schaal Kb, Hoeh Ae, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur. J. Ophthalmol. 19(4), 613–617 (2009).
   PubMed Web of Science ®Google Scholar
• Lim Jw, Ryu Sj, Shin Mc. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J. Ophthalmol. 24(3), 155–158 (2010).
   PubMedGoogle Scholar
• Lim Jw, Kim Mu. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 249(7), 969–974 (2011).
   PubMed Web of Science ®Google Scholar
• Koss Mj, Beger I, Koch Fh. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 26(2), 307–314 (2012).
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng Ys, Zhong L et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171(1), 53–67 (2007).
   PubMed Web of Science ®Google Scholar
• Ford Km, Saint-Geniez M, Walshe T, Zahr A, D'amore Pa. Expression and role of VEGF in the adult retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 52(13), 9478–9487 (2011).
   PubMed Web of Science ®Google Scholar
• Leal Ec, Martins J, Voabil P et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 59(10), 2637–2645 (2010).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Abe R, Jinnouchi Y, Matsui T, Imaizumi T, Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J. Int. Med. Res. 35(6), 896–899 (2007).
   PubMed Web of Science ®Google Scholar
• Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol 12, 20 (2012).
   PubMed Web of Science ®Google Scholar
• Turkcu Fm, Yuksel H, Sahin A et al. Serum dehydroepiandrosterone sulphate, total antioxidant capacity, and total oxidant status in central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. doi:10.1007/s00417-013-2396-2 (2013) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Mazzolani F, Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin Ophthalmol 7, 939–945 (2013).
   PubMedGoogle Scholar
• Castro-Correia J, Coutinho Mf, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc. Ophthalmol. 81(4), 379–386 (1992).
   PubMed Web of Science ®Google Scholar
• Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta. Ophthalmol. Scand. 79(4), 417–421 (2001).
   PubMedGoogle Scholar
• Weenink Ac, Borsje Ra, Oosterhuis Ja. Familial chronic central serous chorioretinopathy. Ophthalmologica 215(3), 183–187 (2001).
   PubMed Web of Science ®Google Scholar
• Gamboa Ol, Pu J, Townend J et al. Electrical estimulation of retinal pigment epithelial cells. Exp. Eye. Res. 91(2), 195–204 (2010).
   PubMed Web of Science ®Google Scholar
• Singh R, Shen W, Kuai D et al. iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration. Hum. Mol. Genet. 22(3), 593–607 (2013).
   PubMed Web of Science ®Google Scholar